托伐普坦治疗急性失代偿期心力衰竭伴低血钠症的近期疗效  

Short-term outcome of tolvaptan in the treatment of acute decompensated heart failure accompanied with hyponatremia

作　　者：张英 

机构地区：[1]济南市第五人民医院内六科,山东济南250021

出　　处：《中国医药科学》2017年第21期66-68,共3页China Medicine And Pharmacy

摘　　要：目的探析对急性失代偿期心力衰竭伴低血钠症患者予以托伐普坦治疗的近期疗效情况。方法选取我院接收诊治的患有急性失代偿期心力衰竭伴低血钠症66例患者为研究资料,经伦理委员会通过依照数字单双号的形式将其分两组,每组33例。实施常规药物治疗对照组,在常规药物治疗的基础上,实施托伐普坦治疗试验组,比较观察试验组和对照组患者的临床治疗效果。结果 75.76%是对照组患者的治疗有效率,显著低于试验组患者的93.94%(P<0.05);经治疗,试验组患者的NT-pro BNP与LVEF指标情况显著低于对照组(P<0.05),试验组患者的Na^+和尿量指标显著高于对照组(P<0.05)。结论对急性失代偿期心力衰竭伴低血钠症患者采取托伐普坦治疗,其治疗效果显著,既能使尿量增加,血钠水平提升,还能使患者的心力衰竭体征得到改善。Objective To investigate the short-term efficacy of tolvaptan in patients with acute deeompensaled heart failure and hyponatremia. Methods 66 cases with acute decompensated heart failure and hyponatremia in our hospital were selected as research data and divided into two groups according to the number of odd and even numbers.The control group were received routine drug treatment,the experimental group received tolvaptan treatment on the basis of routine therapy.clinical curative effect between the experimental group and the control group were compared. Results The effective rate of treatment in the control group （75.76%） was significantly lower lhan that in the experimental group （93.94%） （P 〈 0.05）,The indexes of NT-proBNP and LVEF in the experimental group were significantly lower than those in the control group （P 〈 0.05）,and the Na＋ and urine volume indexes of the experimental group were significantly higher than those of the control group （P 〈 0.05）. Conclusion Using tolvaptan in treatment of acute decompensated heart failure with hyponatremia has significant effect,not only can increase the urine volume,serum sodium level,can make the patients with heart failure symptoms improved.

关 键 词：低血钠症 急性失代偿心衰 托伐普坦 多巴酚丁胺 

分 类 号：R541.6[医药卫生—心血管疾病]